top of page




  1. Dransdeld, O.; Rakatci, I.; Sasson, S.; Gruzman, A.; Smidtt, M.; Haussinger, D.; Eckel, J. Eicosanoids participate in the regulation of cardiac glucose transport by contribution to a rearrangement of actin cytoskeletal elements. Biochem. J. 2001, 359, 4-12. 

  2. Alpert, E&.; Gruzman, A&.; Totary, H&.; Reich, R.; Kaiser, N.; Sasson, S. A natural protective mechanism against hyperglycemia in vascular endothelial and smooth muscle cells: Role of glucose and hydroxyeicosatetranenoic acids. Biochem. J. 2002, 362, 413-422. &-equal contribution.

  3. Bloch-Shilderman, E.; Abu-Raya, S.; Trembovler, V.; Boshwitz, H.; Gruzman, A.; Linial, M.; Lazarovici, P. Pardaxin-stimulation of Phospholipases A2 and their involvement in exocytosis in PC12 cells. J. Pharm. Exp Ther. 2002, 301, 953-962.

  4. Krimsky, M.; Ligumsky, M.; Aptekar, L.; Shwob, U.; Goshen, G.; Gruzman, A.; Sasson, S.; Yedgar, S. Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitors. Am.  J. Physiol.  Gastroinst. Liver Physiology.  2003, 285, G586-592. 

  5. Gruzman, A.; Hidmy, A.; Katzhendler, J.; Haj-Ihie, A.; Sasson, S. Synthesis and characterization of new and potent alpha-Lipoic acid derivatives. Bioorg & Med. Chem. 2004, 12, 1183-1190.

  6. Alpert, E.; Altman, H.; Totary, H.; Gruzman, A.; Barnea, D.; Barash, V.; Sasson, S. 4-hydroxy tempol-induced impairment of mitochondrial function and augmentation of  glucose transport in vascular endothelial and smooth muscle cells. Biochem. Pharmacol. 2004, 67, 1985-1995.

  7. Alpert, E.; Gruzman, A.; Blejter, R.; Aharoni, P.; Weisinger, G.; Eckel, J.; King, L.; Kaiser, N.; Sasson, S. Delayed development of substrate regulation of glucose transport in vascular endothelial cells. Diabetologia, 2005, 48, 752–755. 

  8. Alpert, E.; Gruzman, A.; Lardi-Studler, B.; Cohen, G.; Reich, R.; Sasson, S. Cyclooxygenase-2 (PTGS2) inhibitors augment the rate of hexose transport in L6 myotubes in an insulin- and AMP alpha-independent manner. Diabetologia, 2006, 49, 562-70.

  9. Alpert, E.; Gruzman, A.; Cohen, G.; Tennenbaum, T.; Sasson, S. Selective cyclooxygenas-2 (PTGS2) inhibitors stimulate hexose transport in L6 myotubes in a protein kinase delta dependent mannerBiochem. Pharmacol. 2007, 73, 368-377.

  10. Gruzman, A.; Wood, W.; Alpert, E.; Prasad, D.; Miller, R.; Rothstein, J.; Cleveland, D.; Bowser, R.; Hamilton, R.; Wood, T.; Lingappa, V.,  Liu, J. A common molecular signature in SOD1 for both Sporadic and Familial Amyotrophic Lateral Sclerosis. Proc Natl Acad Sci U S A, 2007, 104, 12524-12529.

  11. Cohen, G.; Riahi, Y.; Alpert, E.; Gruzman, A.; Sasson, S. The roles of hyperglycemia and oxidative stress in the rise and collapse of natural protective mechanism against vascular endothelial cell dysfunction in diabetes. Arch. Physiol. Biochem. 2007, 113, 259-67.

  12. Gruzman, A.; Shamni, O.; Ben Yakir, M.; Sandovski, D.; Elgart, A.; Alpert, E.; Cohen, G.; Hoffman, A.; Cerasi, E.;  Katzhendler, J.;  Sasson, S. Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase. J. Med. Chem. 2008, 51, 8096–8108.

  13. Gruzman, A.; Babai, G.; Sasson, S. Adenosine monophosphate-activated protein kinase (AMPK) as a target for antidiabetic drugs. The RDS, 2009, 6, 13-36.

  14. Riahi, Y.; Sin-Malia, Y.; Cohen, G.; Alpert, E.; Gruzman, A.; Eckel, J.; Staels, B.; Guichardant, M.;  Sasson, S. 4-HDN (4-hydroxydodecadienal) induces downregulation of the glucose transport system in vascular endothelial cells under hyperglycemic conditions by activating PPARdDiabetes, 2010, 59, 808–818.

  15. Liu, L.; Akhavan, A.; Lu, M.; Gruzman, A.; Lingappa, V.; An, J.; Bowser, R. Carbonic anhydrase I is recognized by an SOD1 antibody upon biotinylation of human spinal cord extracts. Int J Mol Sci, 2010, 11, 4051-4062.

  16. Gruzman, A.; Elgart, A.; Viskind, O.;  Billauer, H.;  Dotan, S.; Cohen, G.; Mishani, E.; Hoffman, A.; Cerasi, E.; Sasson, S. Antihyperglycaemic activity of 2,4:3,5-dibenzylidene-D-xylose-dithioacetal in mouse models of type 1 and type 2 diabetes. J Cell Mol Med, 2012, 16(3), 594-604.

  17. Klein, M.; Pulidindi, I.; Perkas, N.; Meltzer-Mats, E.; Gruzman, A.; Gedanken, A. Direct Production of Glucose from Glycogen under Microwave Irradiation. RSC Advances, 2012, 2, 7262-7267.

  18. Braverman, S.; Cherkinsky, M.; Kalendar, Y.;  Gottlieb, H.; Meltzer-Mats, E.; Gruzman, A.; Goldberg, I.; Sprecher, M. One-pot three-component preparation of novel selenium-containing spiroketals. J. Phys. Org. Chem, 2013, 26(2), 102-108.

  19. Meltzer-Mats, E.; Babai, G.; Pasternak, L.; Uritsky, N.; Getter, T.; Viskind, O.; Eckel, J.; Cerasi, E.;  Senderowitz, H.; Sasson, S*.; Gruzman, A*. Synthesis and mechanism of anti-hyperglycemic activity of benzothiazole derivatives. J Med Chem, 2013, 56 (13):5335–5350.

  20. Daniel, B.; Green, O.; Viskind, O.; Gruzman, A*. Riluzole increases the rate of glucose transport in L6 myotubes and NSC-34 motor neuron-like cells via AMPK pathway activation. Amyotroph Lateral Scler Frontotemporal Degener, 2013, 14 (5-6):434–443.

  21. Shapira, R.; Rudnick, S.; Daniel, B.; Viskind, O.; Aisha, V.; Richman, M.; Perelman, A.; Gruzman, A.*; Rahimipour, S. Multifunctional self-assembled cyclic D,L-α-peptide architectures stimulate non-insulin dependent glucose uptake in skeletal muscle cells and protect them against oxidative stress. J Med Chem, 2013, 56(17):6709-6718.

  22. Shimanovich, U*.; Munder, A.; Azoia, N.; Cavaco-Paulo, A.; Gruzman, A.;* Knowles, T.; Gedanken, A*. Sonochemically-induced spectral shift as a probe of green fluorescent protein release from nanocapsules. RSC Advances, 2014, 4:10303–10309.

  23. Shimanovich, U*.; Munder, A.; Loureiro, N.; Azoia, A.; Cavaco-Paulo, A.; Gedanken, A.; Gruzman A*. Gene silencing by synthesized via sonochemical   method siRNA nanoparticlesJ Nanomed Nanotechnol, 2014, 5:204-209.

  24. Zaks, I.; Getter, T.; Gruzman A*. Activators of AMPK – not just for type II diabetes. Future Med Chem, 2014, 6:1325-1353.

  25. Pasternak, L.; Meltzer-Mats, E.; Babay-Shani, G.; Cohen, G.; Viskind, O.; Eckel, J.; Cerasi, E.; Sasson, S*.; Gruzman, A*. Benzothiazole derivatives augment glucose uptake in skeletal muscle cells and stimulate insulin secretion from pancreatic β-cells via AMPK activation. Chem Comm, 2014, 50:11222-11225.

  26. Kahremany, S.; Livne, A.; Gruzman, A.; Senderowitz, H*.; Sasson, S*. Activation of Peroxisome Proliferator Activator Receptor-δ: from computer modelling to biological effects. Br J  Pharmacol, 2015,172:754-770.

  27. Munder, A.; Moskovitz, Y.; Redko, B.; Levy, A.; Ruthstein, S.; Gellerman, G.; Gruzman, A*. Antiproliferative effects of novel aminoacridine-based compounds. Med Chem, 2015, 11: 373-382.

  28. Getter, T.; Zaks, I.; Barhum, T.; Ben-Zur, T.; Böselt, S.; Gregoire, S.;  Viskind, O.; Gottlieb, H.; Shani, T.; Green, O.;  Shubely, M.; Senderowitz, H.; Israelson, A.; Kwon, I.;  Petri, S.; Offen, D.;  Gruzman, A*.  A novel chemical chaperon-based drug candidate is effective in mouse model of amyotrophic lateral sclerosis (ALS), ChemMedChem, 2015, 10: 850 – 861.

  29. Lev, N.;  Barhum, Y.; Ben-Zur, T.;  Aharony, I.; Trifonov, L.; Regev, N.;  Melamed, E.; Gruzman, A.; Offen, D*. DJ-1 based peptide preserves dopaminergic cells in models of Parkinson's diseasePlOS One, 2015, 10.1371.

  30. Weintraub, S.; Moskovits, Y.; Fleker, O.; Levy, R.;  Ruthstein, S.; Benisvy, L*.; Gruzman, A*. SOD mimetic activity of a novel tetra nuclear copper (II) complexJ Inorg Biochem, 2015, 20:1287–1298.

  31. Eckshtain-Levi, M.; Lavi, R.; Yufit, D.; Arora, H.; Daniel, B.; Green, O.; Richman, M.; Rahimipour, S.; Gruzman, A*.;  Benisvy, L*. A Versatile Water-Soluble Chelating and Radical Scavenging Platform. Chem Comm, 2016, 52:2350-2353.

  32. Zer-Aviv, P.; Shubely, M.; Moskovits, Y.; Viskind, O.; Albeck, A.; Vertommen, D.; Ruthstein, S.; Shokhen, M. and Gruzman A*.A new oxopiperazin-based peptidomimetic molecule inhibits prostatic acid phosphatase secretion and induces prostate cancer cells apoptosis. Chemistry Select, 2016, 1: 4658–4667.

  33. Weintraub, S.; Yarnitzky, T.; Kahremany, S.; Barrera, I.; Viskind, O.; Rosenblum, K.; Gruzman, A. Design and synthesis of novel protein kinase R (PKR) inhibitors. Molecular Diversity, 2016, 20(4): 805-819.

  34. Ben-Hail, D.; Begas-Shvartz, R.;  Shalev, M.; Gruzman, A.; Shoshan-Barmatz,  V. The mitochondrial protein VDAC1 as a target for novel anti-apoptotic compounds. J. Biol. Chem, 2016, 291: 24986-25003. 

  35. Munder, A.; L. Israel, L.; Kahremany, S.; Ben-Shabat-Binyamini, R.; Zhang, C.; Kolitz-Domb, M.; Viskind, O.; Levine, A.; Senderowitz, H.; Chessler, S.; Lellouche, J-P*. and Gruzman, A*. Mimicking neuroligin-2 functions in β-cells by functionalized nanoparticles as a novel approach for antidiabetic therapy.  ACS Appl. Mater. Interfaces, 2017, 9:1189−1206. 

  36. Shamni, O.; Cohen, G.; Gruzman, A.; Zaid, H.; Klip, A.; Cerasi, E.; Sasson, S. Regulation of GLUT4 activity in myotubes by 3-O-methyl-D-glucose.  BBA Biomembranes2017, 1859: 1900-1910. 

  37. Shamni, O.; Cohen, G.; Gruzman, A.; Zaid, H.; Klip, A.; Cerasi, E.; Sasson, S. Supportive data on the regulation of GLUT4 activity by 3-O-methyl-D-glucose. Data in Brief, 2017, 14: 329-336.

  38. Rozentul, N.;  Avrahami, Y.; Shubely, M.; Levy, L.; Munder, A.; Cohen, G.; Cerasi, E.; Sasson, S*.; Gruzman, A*. A novel phenylchromane derivative increases the rate of glucose uptake in L6 myotubes and augments insulin secretion in pancreatic beta-cells by activating AMPK. Pharm. Res., 2017, 34: 2873-2890.

  39. Kahremany S.; Babaev I.; Hasin P.; Tamir T.; Ben-Zur T.; Cohen G.; Jiang Z.; Weintraub S.; Offen D.; Rahimipour S.; Major B.; Senderowitz H.; Gruzman A*. Computer-aided design and synthesis of (1-(4-((3,4-dihydroxybenzylidene)amino)phenyl)-5-oxopyrrolidine-3-carboxylic acid) as a novel Nrf2 enhancer. ChemPlusChem. 2018, 83: 320-333.(Cover page).

  40. Trifonov L.; Afri M.; Palczewski K.; Korshin  E*. and Gruzman A*. An Expedient Synthesis of CMF-019: (S)-5-Methyl-3-{1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxamido}hexanoic acid, an Apelin Receptor (APJ) Agonist. Medicinal Chemistry, 2018, 14: 688 – 694.

  41. Shtriker E.; Bretler S.; Munder A.; Byk G.; Cohen G.; Kolitz-Domb M.; Gruzman A*. Hydrogel nanoparticles covered by neuroligin-2-derived peptide-protected β-cells under oxidative stress and increase their proliferation.  Journal of Nanoparticle Research, 2018, 20: 221.

  42. Kahremany S.; Zhenin M.; Shenberger Y.; Maimoun D.; Colotti G.; Arad M.; Shainberg A.; Senderowitz H.; Ruthstein S*.; Gruzman A*. Peptide-based development of PKA activators.  New Journal of Chemistry, 2018, 42: 18585-18597.

  43. Trifonov E.; Nudelman V.; Zhenin M.; Matsree E.; Afri M.; Schmerling B.; Cohen G.; Jozwiak K.; Weitman M.; Korshin E.; Senderowitz H.; Shainberg A.; Hochhauser E*.; Gruzman A*. A peptidomimetic: 1-benzyl-5-methyl-4-(octylamino)pyrimidin-2(1H)-one designed based on the structure of in TLR4 related TRIF-related adaptor molecule (TRAM) - decoy peptide, showed cardio protective effect in myocardial ischemia mouse model. Journal of Medicinal Chemistry, 2018, 61: 11309–11326.

  44. Munder A.; Moskovitz  Y.;  Meir A.; Kahremany S.;  Cohen G.; Kolitz-Domb M .; Shtriker E.; Levy L.;  Viskind O.; Lellouche J-P.;  Senderowitz H.;  Chessler S.; Korshin E.;  Rothshtein S.;  Gruzman A*. Covered by Neuroligin-2-derived peptide polyamidoamine-based (PAMAM) dendrimers enhances pancreatic β-cells' proliferation and functions. MedChemComm., 2019, 10: 280–293. This article is part of the themed collection: Celebrating the 25th EFMC-ISMC (25th International Symposium on Medicinal Chemistry of European Federation of Medicinal Chemistry). The article of the month by Editor chose.

  45. Kahremany S.; Babaev I.;  Gvirtz R.; Ogen-Stern N.; Azoulay-Ginsburg S.; Senderowitz H.; Cohen G.;* Gruzman A*. Activation of the Nrf2 by (E)-5-oxo-1-(4-((2,4,6-trihydroxybenzylidene)amino)phenyl)pyrrolidine-3-carboxylic acid attenuates, oxidative stress, UVB and LPS-induced damage. Skin Pharmacology and Physiology, 2019, 32: 173-181.

  46. Getter T.; Margalit R.; Kahremany S.; Levy L.; Blum E.; Khazanov N.; Keshet-Levy N.Y.; Tamir T.Y.; Ben Major M.; Lahav R.; Zilber S.; Senderowitz H.; Bradfield P.; Imhof B.A.; Alpert E.; Gruzman A. Novel inhibitors of leukocyte transendothelial migration. Bioorganic Chemistry, 2019, 92: 103250.

  47. Meir A.; Lepechkin-Zilbermintz V.;  Kahremany S.; Schwerdtfeger F.;  Gevorkyan-Airapetov L.;  Munder A.; Viskind O.;  Gruzman A.*; Ruthstein S.* Inhibiting the copper efflux system in microbes as a novel approach for developing antibiotics. PLoS One 2019, 14:e0227070.

  48. Azoulay-Ginsburg S.; Trobiani L.; Setini A.; Favaloro F.L.; Giorda E.; Jacob A.; Hauschner H.; Levy L.; Cestra G.; De Jaco A.; Gruzman A. A Lipophilic 4-Phenylbutyric Acid Derivative That Prevents Aggregation and Retention of Misfolded Proteins. Chemistry A European Journal 2020, 26 (8): 1834-1845.

  49. Kahremany S.; Hofmann L.; Gruzman A.; Cohen G. Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch. Int. J. Mol. Sci. 2020, 21(14): 4883.

  50. Blum E.; Zhang J.; Korshin E.; Palczewski K.; Gruzman A.* Development of chiral fluorinated alkyl derivatives of emixustat as drug candidates for the treatment of retinal degenerative diseases. Bioorganic and Medicinal Chemistry Letters2020, 30: 127421.

  51. Trifonov L.; Chumin K.; Gvirtz R.; Afri M.; Korshin E.; Cohen G.*; Gruzman A.* Novel sulfamoylbenzoates as antifungal agents against Malassezia furfur. Mendeleev Communications, 2020, 30: 709–711.

  52. Rippin I.; Khazanov N.; Ben Joseph S.; Kudinov T.; Berent E.; Marciano D.; Ruiz S. M. A.; Levy L.; Gruzman A.; Senderowitz H.; Eldar-Finkelman H. Discovery and design of novel small molecule GSK-3 inhibitors targeting the substrate binding site. International Journal of Molecular Sciences, 2020, 21: 8709.

  53. Manikoth Ayyathan D.; Levy-Cohen G.; Shubely M.; Boutros-Suleiman S.; Lepechkin-Zilbermintz V.; Shokhen M.; Albeck A.; Gruzman A.; Blank M. Development and characterisation of SMURF2-targeting modifiers. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36 (1): 401-409.

  54. Kahremany S.; Hofmann L.; Harari M, Gruzman A.; Cohen G. Dermal Itch in Psoriasis and Atopic Dermatitis: Current Treatments and New Perspectives. Pharmacological Reports, 2021, 73:443-453. 

  55. Azoulay-Ginsburg S.; Di Salvio M.; Ribeiro S.; Weitman M.; Afri M.;  Ebbinghaus S.; Cestra G.; Gruzman A. Chemical Chaperones Targeted to ER and Lysosome Prevented Neurodegeneration in a C9orf72 Repeat Expansion Drosophila ALS Model. Pharmacological Reports, 2021, 73:536-550. 

  56. Blum E.; Zhang J.; Zaluski J.; Einstein D.; E., Korshin E. E.; Kubas A.; Gruzman A.; Tochtrop G. P.; Kiser P. D.; Palczewski K.  Rational Alteration of Pharmacokinetics of Chiral Fluorinated and Deuterated Derivatives of Emixustat for Retinal Therapy.  Journal of Medicinal Chemistry, 2021, 64:8287–8302.

  57. Bianchetti G.; Azoulay-Ginsburg S.; Keshet-Levy N. Y.; Malka A.; Zilber S.; Korshin E. E.; Sasson S.; De Spirito M.; Gruzman A.; Maulucci G. Investigation of the membrane fluidity regulation of fatty acid intracellular distribution by fluorescence lifetime imaging of polarity sensitive fluorescent analogs of fatty acids/laurdan. International Journal of Molecular Sciences (Special Issue: "Molecular Imaging in Nanomedical Research"), 2021, 22(6):3106.

  58. Blum E.; Margalit R.; Levy L.; Getter T.; Lahav R.; Zilber S.; Bradfield P.; Imhof B. A.; Alpert E.; Gruzman A.* A potent leukocyte transmigration blocker: GT-73 showed a protective effect against LPS-induced ARDS in mice. Molecules (Special Issue: “Chemical Biology”) 2021, 26: 4583.

  59. Alpert E.; Akhavan A.; Gruzman A.; Hansen W. J.; Lehrer- Graiwer J.;  Witkowski H. E.; Hall S.C.; Johansen E.; McAllister S.; Gulati M.; Lin M-F.;  Lingappa V.R*. Multifunctionality of Prostatic Acid Phosphatase in Prostate Cancer Pathogenesis. Bioscience Reports, 2021, 41, BSR2021, 1646. 

  60. Trifonov L.; Rothstein A.;  Korshin E. E.; Viskind O.;  Afri M.; Leitus G.; Palczewski K.; Gruzman A. Straightforward Access to Terminally Disubstituted Electron-Deficient Alkylidene Cyclopent-2-en-4-ones through a Stepwise or Tandem Base-Promoted pseudo-Tsuji-Trost Allylation and Vinylogous retro-Michael Dehydrosulfinylation. European Journal of Organic Chemistry, 2021, 48: 6725-6736.

  61. Kahremany S.; Hofmann L.; Eretz-Kdosha N.; Silberstein E.; Gruzman A.*; Cohen G.* SH-29 and SK-119 attenuates air-pollution induced damage by activating Nrf2 in HaCaT cells. International Journal of Environmental Research and Public Health, 2021, 18(23): 12371.

  62. Lior Y.; Shtriker E.; Kahremany S.; Lewis E.; Gruzman A.* Development of anti-inflammatory peptidomimetics based on the structure of human alpha1-antitrypsin. European Journal of Medicinal Chemistry, 2022, 228: 113969.

  63. Trifonov L.; Yurchenko M.; Skjesol A.; Cohen G.; Espevik T.;  Korshin E. E.; Husebye H.;* Gruzman A.* Benzyl-para-di-[5-methyl-4-(n-octylamino)pyrimidin-2(1H)one] as an Interferon beta (IFN-β) modulator. Molecular Diversity, 2022, 26: 2175–2188.

  64. Kahremany S.; Hofmann L.; Gruzman A.; Cohen G.; Dinkova-Kostova A. Nrf2 in dermatological disorders: pharmacological activation for protection against cutaneous photodamage and photodermatosis.  Free Radical Biology and Medicine, 2022, 188: 262-276.

  65. Alfahel L.; Argueti-Ostrovsky S.; Barel S.; Ali Saleh M.; Kahn J.; Azoulay-Ginsburg S.; Rothstein A.; Ebbinghaus S.; Gruzman A.; Israelson A*. 4-Phenylbutyric Acid (4-PBA) Derivatives Prevent SOD1 Amyloid Aggregation In Vitro with No Effect on Disease Progression in SOD1-ALS Mice. International Journal of Molecular Sciences. Special Issue: “Molecular Research on Amyotrophic Lateral Sclerosis”, 2022, 23: 9403.

  66. Lepechkin-Zilbermintz V.; Bareket B.; Gonnord V.; Steffen A.; Morice C.; Michaut M.; Munder A.; Korshin E. E.; Contreras J-M.; Cerasi E.; Sasson S.; Gruzman A.*. Moderately lipophilic 2-(Het)aryl-6-dithioacetals, 2-phenyl-1,4-benzodioxane-6-dithioacetals and 2-phenylbenzofuran-5-dithioacetals: Synthesis and primary evaluation as potential antidiabetic AMPK-activators. Bioorganic and Medicinal Chemistry, 2023, 87:117303.

  67. Lubart R.; Yariv I.; Fixler D.; Rothstein A.; Gruzman A.; Lipovsky A.*. A novel facial cream based on skin penetrable Hemp oil microparticles. Journal of Cosmetics, Dermatological Sciences and Applications, 2023, 13:165-178.

  68. Ribeiro S.; Gnutt D.; Azoulay-Ginsburg S.; Zamira Fetahaj Z.; Spurlock E.; Lindner F.; Kuz D.; Cohen-Erez Y.; Rapaport H.; Israelson A.; Gruzman A*.; Ebbinghaus S*. Intracellular spatially-targeted chemical chaperones increase native state stability of mutant SOD1 barrel. Accepted in Biological Chemistry, 2023.



  1. Lingappa, V.; Liu, J.; Gruzman, A. (2006). Biomarkers for Amyotrophic Lateral Sclerosis. US patent application 60/061,632.

  2. Sasson, S.; Cerasi, E.; Gruzman, A.; Katzhendler, (2010). Development of novel anti-hyperglycemic drugs. US granted patent 7,812,142.

  3. Sasson, S.; Cerasi, E.; Gruzman, A.; Meltzer-Matz, E. (2011). United States patent registration PCT61/513,802. Ethoxybenzo-thiazol derivatives as a basis for development of novel oral antidiabetic drugs.

  4. Getter T.; Zaks I.; Green O.; Offen D.; Gruzman A. (2015). Intracellular targeted chemical chaperones and uses thereof in the treatment of diseases. Application number: 62109644

  5. Munder, A.; Chessler, S.; Lellouche, J-P. and  Gruzman A. (2016). Compositions and methods for  enhancing beta cell maturation, health and function.  U.S. provisional patent application No. 62/432,212.

  6. Gruzman, A.; Getter, T.; Imhof, B.; Bradfield, P.; Matthes, T.; Senderowitz, H. (2017). Novel barbituric acid based leucocyte transmigration inhibitors as drug candidates for treating inflammatory diseases, autoimmune diseases and cancer. Provisional patent application number: 62552491.

  7. Shoshan-Barmatz V. and Gruzman A. (2017). Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunctions. Provisional patent application number 65102000.

  8.  Hochhauser, E.; Gruzman, A.; and Trifonov, L.; (2018). Toll-like receptor 4 (TLR4) inhibitors and use thereof. Provisional Patent Application, USP P10647.

  9. Shoshan-Barmatz V and  Gruzman A. (2018). Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors. US Patent App. 15/700,801.

  10. Las G, Gruzman A,  Cerqueira F, Shirihai O (2018).  “Novel benzothiophene derivatives and use thereof in stimulating mitochondrial turnover",  U.S. Provisional Patent Application No. 62/677,076.



  1. Gruzman, A. "Solutions for pharmaceutical license examines in Israel, USA, and Canada" Editor: Ludensky S., Kriger Research & Education Center. Tel-Aviv, New York, Toronto, Frankfurt, 1999.

  2. Gruzman, A.; Ermolaev, G. "Supplementary material: Solutions for pharmaceutical license examines in Israel, USA and Canada'' Editor: Ludensky S., Kriger Research & Education Center. Tel-Aviv, New-York, Toronto, Frankfurt. 2000.




bottom of page